Healthcare speed-scaling platform offers clinical validation, regulatory support, mentorship, and investor access to startups working across preventive health, oncology, genomics, diagnostics, and digital health
Chronic GVHD is a serious and potentially life-threatening condition, imposing profound physical and emotional burdens on a substantial proportion of patients following allogeneic stem cell transplantation
Co-founder and previous CEO Lowry Curley becomes Chief Scientific Officer
It adds Rezurock (belumosudil) an FDA-approved, first-in-class treatment for adult and pediatric patients 12 years and older with chronic graft-versus-host disease (cGVHD)
Subscribe To Our Newsletter & Stay Updated
